SCHEMBL29638840

SCHEMBL29638840

Cc1nc(C2[C@H]3CN(C(=O)OC(C)(C)C)C[C@@H]23)cs1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.43
MAPT P10636 1/20 0.43
SSTR4 P31391 1/20 0.41
USP30 Q70CQ3 3/20 0.40
NR1H2 P55055 1/20 0.38
JAK3 P52333 1/20 0.38
EED O75530 1/20 0.36
RBBP4 Q09028 1/20 0.36
SUZ12 Q15022 1/20 0.36
EZH2 Q15910 1/20 0.36
AEBP2 Q6ZN18 1/20 0.36
GPR119 Q8TDV5 2/20 0.36
NAMPT P43490 1/20 0.36
SMARCA2 P51531 1/20 0.35
SMARCA4 P51532 1/20 0.35
PBRM1 Q86U86 1/20 0.35
PIK3CA P42336 1/20 0.35
RORC P51449 1/20 0.35
HTT P42858 1/20 0.34
ATM Q13315 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21137404 1.00 KDM4E (0.43) KDM4EMAPTSSTR4USP30NR1H2
SCHEMBL20586011 0.81 RAB9A (0.38) KDM4EHTT
SCHEMBL20586012 0.81 RAB9A (0.38) KDM4EHTT
SCHEMBL20586014 0.81 RAB9A (0.38) KDM4EHTT
SCHEMBL20587746 0.81 RAB9A (0.38) KDM4EHTT
SCHEMBL2279416 0.80 KDM4E (0.48) KDM4EMAPTUSP30EEDRBBP4
SCHEMBL22326469 0.80 SSTR4 (0.43) SSTR4USP30NR1H2JAK3EED
SCHEMBL16210462 0.78 SSTR4 (0.39) SSTR4USP30NR1H2JAK3GPR119
SCHEMBL16210459 0.78 SSTR4 (0.39) SSTR4USP30NR1H2JAK3GPR119
SCHEMBL16210458 0.78 SSTR4 (0.39) SSTR4USP30NR1H2JAK3GPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3638658-B1 PHARMACEUTICAL COMPOUNDS NXERA PHARMA UK LTD (GB) 2025-10-08 EP disclosed
CN-110944992-B Pharmaceutical compounds 赫普泰雅治疗有限公司 2023-05-16 CN disclosed
US-11352342-B2 Pharmaceutical compounds HEPTARES THERAPEUTICS LIMITED (GB) 2022-06-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11352342-B2 Pharmaceutical compounds CHRM1, CHRM2, CHRM4 KDM4E 3256/4885MAPT 1525/4885SSTR4 391/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.